First Author: M.Genaidy EGYPT
Back to previous
To assess treatment with IRIDEX IQ 532™ (green) subthreshold micropulse laser in patients with recurrent and chronic central serous chorioretinopathy (cCSC).
Ophthalmology department, Faculty of Medicine, Minia University, Minia, Egypt
This retrospective study included 27 patients treated with a 532-nm SML (Iridex) for CSC. 12 cases had recurrent type and 15 case had chronic CSC. Assessment included visual acuity (VA), central retinal thickness (CRT) and resolution of SRF
Follow-up (mean 6 months), 100% of the recurrent type completely cured between one and 3 months and the CRT decreased (mean 130 um). 80% of the chronic cases responded to treatment between 3 to 9 months and the CRT decreased (mean 86 um). VA improved in both groups. No complications from the treatment were detected in all imaging techniques.
The IQ 532™ (green) SML is an effective treatment for recurrent and chronic CSC